Skip to main content

Advertisement

SpringerLink
Log in

A Physiologically Based Pharmacokinetic Model of Mitoxantrone in Mice and Scale-up to Humans: a Semi-Mechanistic Model Incorporating DNA and Protein Binding

  • Research Article
  • Published:
The AAPS Journal Aims and scope Submit manuscript

Abstract

We conducted a pharmacokinetic (PK) study of mitoxantrone (Novantrone®), a clinically well-established anticancer agent, in mice and developed a mechanism-based PBPK (physiologically based pharmacokinetic) model to describe its disposition. Mitoxantrone concentrations in plasma and six organs (lung, heart, liver, kidney, spleen, and brain) were determined after a 5 mg/kg i.v. dose. We evaluated three different PBPK models in order to characterize our experimental data: model 1 containing Kp values, model 2 incorporating a deep binding compartment, and model 3 incorporating binding of mitoxantrone to DNA and protein. Among the three models, only model 3 with DNA and protein binding captured all the experimental data well. The estimated binding affinity for DNA (K DNA) and protein (K macro) were 0.0013 and 1.44 μM, respectively. Predicted plasma and tissue AUC values differed from observed values by <19 %, except for heart (60 %). Model 3 was further used to simulate plasma mitoxantrone concentrations in humans for a 12-mg/m2 dose, using human physiological parameters. The simulated results generally agreed with the observed time course of mitoxantrone plasma concentrations in patients after a standard dose of 12 mg/m2. In summary, we reported for the first time a mechanism-based PBPK model of mitoxantrone incorporating macromolecule binding which may have clinical applicability in optimizing clinical therapy. Since mitoxantrone is a substrate of the efflux transporters ABCG2 and ABCB1, the incorporation of efflux transporters may also be necessary to characterize the data obtained in low-dose studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Smith IE. Mitoxantrone (novantrone): a review of experimental and early clinical studies. Cancer Treat Rev. 1983;10:103–15.

    Article  PubMed  CAS  Google Scholar 

  2. Batra VK, Morrison JA, Woodward DL, Siverd NS, Yacobi A. Pharmacokinetics of mitoxantrone in man and laboratory animals. Drug Metab Rev. 1986;17:311–29.

    Article  PubMed  CAS  Google Scholar 

  3. Durr FE, Wallace RE, Citarella RV. Molecular and biochemical pharmacology of mitoxantrone. Cancer Treat Rev. 1983;10(Suppl B):3–11.

    Article  PubMed  Google Scholar 

  4. Young CW, Raymond V. Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives. Cancer Treat Rep. 1986;70:51–63.

    PubMed  CAS  Google Scholar 

  5. Scott LJ, Figgitt DP. Mitoxantrone: a review of its use in multiple sclerosis. CNS Drugs. 2004;18:379–96.

    Article  PubMed  CAS  Google Scholar 

  6. Ehninger G, Schuler U, Proksch B, Zeller KP, Blanz J. Pharmacokinetics and metabolism of mitoxantrone. A review. Clin Pharmacokinet. 1990;18:365–80.

    Article  PubMed  CAS  Google Scholar 

  7. De Isabella P, Palumbo M, Sissi C, Capranico G, Carenini N, Menta E, Oliva A, Spinelli S, Krapcho AP, Giuliani FC, et al. Topoisomerase II DNA cleavage stimulation, DNA binding activity, cytotoxicity, and physico-chemical properties of 2-aza- and 2-aza-oxide-anthracenedione derivatives. Mol Pharmacol. 1995;48:30–8.

    PubMed  Google Scholar 

  8. Thielmann HW, Popanda O, Gersbach H, Gilberg F. Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts. Carcinogenesis. 1993;14:2341–51.

    Article  PubMed  CAS  Google Scholar 

  9. Foye WO, Vajragupta O, Sengupta SK. DNA-binding specificity and RNA polymerase inhibitory activity of bis(aminoalkyl)anthraquinones and bis(methylthio)vinylquinolinium iodides. J Pharm Sci. 1982;71:253–7.

    Article  PubMed  CAS  Google Scholar 

  10. Lu K, Savaraj N, Loo TL. Pharmacological disposition of 1,4-dihydroxy-5-8-bis[[2 [(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione dihydrochloride in the dog. Cancer Chemother Pharmacol. 1984;13:63–6.

    Article  PubMed  CAS  Google Scholar 

  11. Reszka R, Beck P, Fichtner I, Hentschel M, Richter J, Kreuter J. Body distribution of free, liposomal and nanoparticle-associated mitoxantrone in B16-melanoma-bearing mice. J Pharmacol Exp Ther. 1997;280:232–7.

    PubMed  CAS  Google Scholar 

  12. Ehninger G, Proksch B, Heinzel G, Schiller E, Weible KH, Woodward DL. The pharmacokinetics and metabolism of mitoxantrone in man. Invest New Drugs. 1985;3:109–16.

    Article  PubMed  CAS  Google Scholar 

  13. Richard B, Fabre G, Fabre I, Cano JP. Excretion and metabolism of mitoxantrone in rabbits. Cancer Res. 1989;49:833–7.

    PubMed  CAS  Google Scholar 

  14. Alberts DS, Peng YM, Leigh S, Davis TP, Woodward DL. Disposition of mitoxantrone in cancer patients. Cancer Res. 1985;45:1879–84.

    PubMed  CAS  Google Scholar 

  15. Sharom FJ. ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics. 2008;9:105–27.

    Article  PubMed  CAS  Google Scholar 

  16. Gerlowskiand LE, Jain RK. Physiologically based pharmacokinetic modeling: principles and applications. J Pharm Sci. 1983;72:1103–27.

    Article  Google Scholar 

  17. Gustafson DL, Rastatter JC, Colombo T, Long ME. Doxorubicin pharmacokinetics: macromolecule binding, metabolism, and excretion in the context of a physiologic model. J Pharm Sci. 2002;91:1488–501.

    Article  PubMed  CAS  Google Scholar 

  18. Bradshaw-Pierce EL, Eckhardt SG, Gustafson DL. A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Clin Cancer Res. 2007;13:2768–76.

    Article  PubMed  CAS  Google Scholar 

  19. Zaharko DS, Dedrick RL, Bischoff KB, Longstreth JA, Oliverio VT. Methotrexate tissue distribution: prediction by a mathematical model. J Natl Cancer Inst. 1971;46:775–84.

    PubMed  CAS  Google Scholar 

  20. Li J, Gwilt P. The effect of malignant effusions on methotrexate disposition. Cancer Chemother Pharmacol. 2002;50:373–82.

    Article  PubMed  CAS  Google Scholar 

  21. Bischoff KB, Dedrick RL, Zaharko DS, Longstreth JA. Methotrexate pharmacokinetics. J Pharm Sci. 1971;60:1128–33.

    Article  PubMed  CAS  Google Scholar 

  22. Farris FF, Dedrick RL, King FG. Cisplatin pharmacokinetics: applications of a physiological model. Toxicol Lett. 1988;43:117–37.

    Article  PubMed  CAS  Google Scholar 

  23. Shah DK, Balthasar JP. Physiologically based pharmacokinetic model for topotecan in mice. J Pharmacokinet Pharmacodyn. 2011;38:121–42.

    Article  PubMed  CAS  Google Scholar 

  24. An G, Morris ME. HPLC analysis of mitoxantrone in mouse plasma and tissues: application in a pharmacokinetic study. J Pharm Biomed Anal. 2010;51:750–3.

    Article  PubMed  CAS  Google Scholar 

  25. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10:1093–5.

    Article  PubMed  CAS  Google Scholar 

  26. Goormaghtigh E, Chatelain P, Caspers J, Ruysschaert JM. Evidence of a specific complex between adriamycin and negatively-charged phospholipids. Biochim Biophys Acta. 1980;597:1–14.

    Article  PubMed  CAS  Google Scholar 

  27. Courtade S, Marinetti GV, Stotz E. The structure and abundance of rat tissue cardiolipins. Biochim Biophys Acta. 1967;137:121–34.

    PubMed  CAS  Google Scholar 

  28. Kawai R, Mathew D, Tanaka C, Rowland M. Physiologically based pharmacokinetics of cyclosporine A: extension to tissue distribution kinetics in rats and scale-up to human. J Pharmacol Exp Ther. 1998;287:457–68.

    PubMed  CAS  Google Scholar 

  29. Terasaki T, Iga T, Sugiyama Y, Hanano M. Pharmacokinetic study on the mechanism of tissue distribution of doxorubicin: interorgan and interspecies variation of tissue-to-plasma partition coefficients in rats, rabbits, and guinea pigs. J Pharm Sci. 1984;73:1359–63.

    Article  PubMed  CAS  Google Scholar 

  30. Terasaki T, Iga T, Sugiyama Y, Hanano M. Experimental evidence of characteristic tissue distribution of adriamycin. Tissue DNA concentration as a determinant. J Pharm Pharmacol. 1982;34:597–600.

    Article  PubMed  CAS  Google Scholar 

  31. Peng YM, Ormberg D, Alberts DS, Davis TP. Improved high-performance liquid chromatography of the new antineoplastic agents bisantrene and mitoxantrone. J Chromatogr. 1982;233:235–47.

    Article  PubMed  CAS  Google Scholar 

  32. Larson RA, Daly KM, Choi KE, Han DS, Sinkule JA. A clinical and pharmacokinetic study of mitoxantrone in acute nonlymphocytic leukemia. J Clin Oncol. 1987;5:391–7.

    PubMed  CAS  Google Scholar 

  33. Alberts DS, Peng YM, Leigh S, Davis TP, Woodward DL. Disposition of mitoxantrone in patients. Cancer Treat Rev. 1983;10(Suppl B):23–7.

    Article  PubMed  Google Scholar 

  34. Lown JW, Hanstock CC. High field 1H-NMR analysis of the 1:1 intercalation complex of the antitumor agent mitoxantrone and the DNA duplex [d(CpGpCpG)]. J Biomol Struct Dyn. 1985;2:1097–106.

    PubMed  CAS  Google Scholar 

  35. Kapuscinski J, Darzynkiewicz Z. Relationship between the pharmacological activity of antitumor drugs Ametantrone and mitoxantrone (Novatrone) and their ability to condense nucleic acids. Proc Natl Acad Sci U S A. 1986;83:6302–6.

    Article  PubMed  CAS  Google Scholar 

  36. Rentsch KM, Schwendener RA, Pestalozzi BC, Sauter C, Wunderli-Allenspach H, Hanseler E. Pharmacokinetic studies of mitoxantrone and one of its metabolites in serum and urine in patients with advanced breast cancer. Eur J Clin Pharmacol. 1998;54:83–9.

    Article  PubMed  CAS  Google Scholar 

  37. Rentsch KM, Horber DH, Schwendener RA, Wunderli-Allenspach H, Hanseler E. Comparative pharmacokinetic and cytotoxic analysis of three different formulations of mitoxantrone in mice. Br J Cancer. 1997;75:986–92.

    Article  PubMed  CAS  Google Scholar 

  38. Wang YF, Ahmad A, Abu-Qare AW, Dudkowski C, Ayoub JE, Zhang A, Ahmad I. Rapid determination of liposomal and non-liposomal mitoxantrone in mouse plasma. Preclinica. 2004;2:279–86.

    CAS  Google Scholar 

  39. Mao Q, Unadkat JD. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J. 2005;7:E118–33.

    Article  PubMed  CAS  Google Scholar 

  40. Zhang S, Yang X, Morris ME. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport. Mol Pharmacol. 2004;65:1208–16.

    Article  PubMed  CAS  Google Scholar 

  41. Minderman H, Suvannasankha A, O'Loughlin KL, Scheffer GL, Scheper RJ, Robey RW, Baer MR. Flow cytometric analysis of breast cancer resistance protein expression and function. Cytometry. 2002;48:59–65.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

Supported in part by a grant from the Susan G. Komen Breast Cancer Foundation (BCTR0601385). We thank Dr. Donald Mager and Dr. Chao Xu for their valuable suggestions in the PBPK model construction.

Author information

Author notes

  1. Guohua An

    Present address: Department of Clinical Pharmacology and Pharmacometrics, Abbott Laboratories, Abbott Park, Illinois, USA

Authors and Affiliations

  1. Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, State University of New York, 517 Hochstetter Hall, Amherst, New York, 14260-1200, USA

    Guohua An & Marilyn E. Morris

Authors
  1. Guohua An
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marilyn E. Morris
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marilyn E. Morris.

Rights and permissions

Reprints and permissions

About this article

Cite this article

An, G., Morris, M.E. A Physiologically Based Pharmacokinetic Model of Mitoxantrone in Mice and Scale-up to Humans: a Semi-Mechanistic Model Incorporating DNA and Protein Binding. AAPS J 14, 352–364 (2012). https://doi.org/10.1208/s12248-012-9344-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12248-012-9344-7

KEY WORDS

Search

Navigation